Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials

Everolimus (EVR) in heart and renal transplant (RTx) recipients may be associated with a decreased incidence of cytomegalovirus (CMV). A detailed analysis of the association between EVR versus mycophenolic acid (MPA) and CMV events has not been reported. CMV data from 2004 de novo RTx recipients from three‐randomized, prospective, EVR studies A2309 (N = 833), B201 (N = 588) and B251 (N = 583) were retrospectively analyzed to identify differences between two EVR dosing groups and MPA. EVR groups received 1.5 mg/day, or 3 mg/day with either standard (SD‐CsA) or reduced dose cyclosporine (RD‐CsA). Controls received MPA with SD‐CsA. CMV prophylaxis was as per center practice. CMV incidence (infection/syndrome, disease, viremia) was captured per local center evaluations. Kaplan–Meier analyses demonstrated that freedom from CMV viremia and infection/syndrome was significantly greater for EVR versus MPA for recipients without CMV prophylaxis. Among recipients who received prophylaxis, freedom from viremia was greater for EVR 3.0 mg; freedom from infection/syndrome was greater for EVR 3.0 and 1.5 mg. Although freedom from organ involvement was numerically greater for EVR, it was not statistically significant. This analysis documents significant reductions in the incidence of CMV infection/syndrome and viremia in EVR‐treated de novo RTx recipients, especially those who did not receive CMV prophylaxis versus MPA.

[1]  A. Webster,et al.  Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. , 2013, The Cochrane database of systematic reviews.

[2]  J. Alwine,et al.  The Changing Role of mTOR Kinase in the Maintenance of Protein Synthesis during Human Cytomegalovirus Infection , 2011, Journal of Virology.

[3]  J. Pascual,et al.  Immunosuppressive therapy and infection after kidney transplantation , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[4]  K. Salmela,et al.  Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  T. Reischig.  Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies , 2010, Expert review of anti-infective therapy.

[6]  P. Reinke,et al.  Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial , 2010, Transplantation.

[7]  Y. S. Kim,et al.  Everolimus Plus Reduced‐Exposure CsA versus Mycophenolic Acid Plus Standard‐Exposure CsA in Renal‐Transplant Recipients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  T. Shenk,et al.  Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication , 2010, Journal of Virology.

[9]  M. Viganó,et al.  Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[10]  O. Hes,et al.  Effect of Cytomegalovirus Viremia on Subclinical Rejection or Interstitial Fibrosis and Tubular Atrophy in Protocol Biopsy at 3 Months in Renal Allograft Recipients Managed by Preemptive Therapy or Antiviral Prophylaxis , 2009, Transplantation.

[11]  D. Giakoustidis,et al.  Use of everolimus in de novo renal recipients: initial experience in the Greek population. , 2008, Transplantation proceedings.

[12]  M. Blum,et al.  Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. , 2008, Transplantation proceedings.

[13]  F. Cosio,et al.  Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  H. Rollag,et al.  Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk , 2007, Clinical Transplantation.

[15]  J. Pascual,et al.  12‐month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  A. Hartmann,et al.  The Natural Course of Cytomegalovirus Infection and Disease in Renal Transplant Recipients , 2006, Transplantation.

[17]  S. Gruber,et al.  Infectious complications after kidney transplantation: current epidemiology and associated risk factors , 2006, Clinical transplantation.

[18]  A. Webster,et al.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. , 2006, The Cochrane database of systematic reviews.

[19]  H. Rollag,et al.  Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced β-cell damage , 2005 .

[20]  W. Weimar,et al.  Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  S. Mulgaonkar,et al.  Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study , 2005, Transplantation.

[22]  F. Jarraya,et al.  Infectious complications in kidney transplant recipients: a single-center experience. , 2005, Transplantation proceedings.

[23]  O. Hes,et al.  Valacyclovir for Cytomegalovirus Prophylaxis Reduces the Risk of Acute Renal Allograft Rejection , 2005, Transplantation.

[24]  Raimund Margreiter,et al.  Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients , 2004, Transplantation.

[25]  H. Kim,et al.  Viral infection following kidney transplantation: long-term follow-up in a single center. , 2004, Transplantation proceedings.

[26]  H. Rollag,et al.  Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. , 2004, Kidney international.

[27]  B. Alexander,et al.  Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  Julio Pascual,et al.  Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6‐Month Safety and Efficacy Results of Two Randomized Studies , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  M. Schnitzler.  Costs and consequences of cytomegalovirus disease. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[30]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[31]  Y. Becker,et al.  Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  C. Legendre,et al.  VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATION , 2000, Transplantation.

[33]  W. Kim,et al.  The economic impact of cytomegalovirus infection after liver transplantation. , 2000, Transplantation.

[34]  J. Squifflet,et al.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.

[35]  M. Schnitzler,et al.  Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. , 1997, Transplantation.

[36]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[37]  J. Kletzmayr,et al.  Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. , 1996, Journal of the American Society of Nephrology : JASN.

[38]  A. Webster,et al.  Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. , 2005, The Cochrane database of systematic reviews.

[39]  L. Rostaing,et al.  CMV prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: a prospective study. , 1997, American journal of nephrology.